Diabetes drug trialled for weight loss

Liraglutide therapy as an adjunct to diet and exercise results in “clinically meaningful” weight loss in obese people without diabetes compared to diet and exercise alone, according to an international study.

The 56-week trial randomised people with a BMI of 30 or over but without diabetes to 3mg liraglutide or placebo, with both groups receiving counselling on lifestyle modification.

At 56 weeks, those in the liraglutide arm showed significant improvements in weight and metabolic control compared with placebo.